HCPCS 2018

Q0180 Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
Added on: Wednesday, April 04, 1998
Status changed on: Wednesday, April 04, 1998
BETOS Classification : Chemotherapy
Medicare coverage status:Special coverage instructions apply